Setanaxib

Setanaxib (development code GKT-831) is an experimental orally <a href="/facts/Bioavailability/9l6na9MV">bioavailable</a> dual inhibitor of <a href="/facts/NADPH_oxidase/x0f5sfNn">NADPH oxidase</a> isoforms <a href="/facts/NOX4/h5oYgWsb">NOX4</a> and <a href="/facts/NOX1/loRmr4KV">NOX1</a>. Setanaxib is a member of the pyrazolopyridine dione chemical series. The compound is the only specific NOX inhibitor that has entered into <a href="/facts/Clinical_trial/q8LMr832">clinical trials</a>.
Setanaxib has demonstrated biological activity in a number of in vitro and in vivo animal pharmacological models including <a href="/facts/Squamous_cell_carcinoma_of_the_head_and_neck/v8T8bNs7">squamous cell carcinoma of the head and neck</a>, <a href="/facts/Diabetic_nephropathy/GHmG7ofQ">diabetic nephropathy</a>, <a href="/facts/Retinopathy/hJNgzmdh">retinopathy</a>, <a href="/facts/Atherosclerosis/WIS8QQ6v">atherosclerosis</a>, <a href="/facts/Liver_fibrosis/bkLuLvCD">liver fibrosis</a>, <a href="/facts/Osteoporosis/xa1W00Tj">osteoporosis</a>, <a href="/facts/Pulmonary_hypertension/4848aBJl">pulmonary hypertension</a>, and <a href="/facts/Idiopathic_pulmonary_fibrosis/NhAoCEqb">idiopathic pulmonary fibrosis</a>. This drug candidate has been investigated in humans in a Phase 2 proof-of-concept trial in <a href="/facts/Primary_biliary_cholangitis/9X0f10mz">primary biliary cholangitis</a> and a Phase 2 proof-of-concept trial in diabetic nephropathy.
Setanaxib was developed by Genkyotex, a French biotech company based in <a href="/facts/Archamps/C7zm50qU">Archamps</a>. In 2020, <a href="https://www.calliditas.se/en/">Calliditas Therapeutics AB</a> acquired a controlling interest in Genkyotex, which was delisted and became a fully owned subsidiary of Calliditas in October 2021. Calliditas, a commercial stage biotech company headquartered in <a href="/facts/Stockholm/sD74W4Pm">Stockholm</a>, is currently developing setanaxib in two clinical trials in human patients.

Setanaxib open-in-new

Setanaxib